Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:22 AM
Ignite Modification Date:
2025-12-25 @ 12:22 AM
NCT ID:
NCT05289258
Eligibility Criteria:
Inclusion Criteria:
* Cancer diagnosis, stages I-III.
* Cancer type: Breast.
* Have received the last chemotherapy session in the last 6 months and a maximum of 6 years of treatment completion.
* Probable or mild to moderate cognitive impairment (score between 26 and 10 points according to the MMSE).
* Ability to be fluent in Spanish.
* Not currently participating in another clinical trial.
* Not currently receiving other psychological treatment
Exclusion Criteria:
* Men and women aged \> 70 years.
* Diagnosis of cancer, stage IV or other types of cancer.
* Last chemotherapy session \< 6 months or \> 6 years.
* No cognitive impairment (MMSE score between 30 and 27 points).
* Diagnosis of mental disorder (including substance abuse) prior to cancer diagnosis.
* Relapse in disease after chemotherapy treatment is completed.
* Neurodevelopmental Disorder Diagnosis.
* Diagnosis of diseases that affect cognitive performance such as: hypertension, cardiac diseases, epilepsy, dementias, multiple sclerosis, functional disorders (fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, post-concussion syndrome, whiplash syndrome), CNS infections (HIV, encephalitis), metabolic disorders (diabetes, B12 deficiency), obstructive sleep apnea, brain damage (stroke, TBI, CNS cancer) and use of medications / substances that interfere with cognitive function such as pregabalin, gabapentin, topiramate, antidepressants tricyclics, sodium valproate, anticholinergics, methylphenidate, typical antipsychotics.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
70 Years
Study:
NCT05289258
Study Brief:
Protocol Section:
NCT05289258